Australia  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Imugene adds key members to its scientific advisory board to advance company forward

Proactive Investors Friday, 11 January 2019
Imugene Ltd (ASX:IMU) CEO Leslie Chong sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. Imugene is an Australian biotechnology company with operations in the U.S. and in Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

Imugene doses first patient in phase-two study of cancer vaccine

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong speaks to Proactive Investors about the pharma and biotech company’s HER-Vaxx (IMU-131) cancer...
Proactive Investors

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development plan

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its...
Proactive Investors


Other recent news in Business

PM to outline Victorian HEALTH packageTech giants face fines upwards of $100 million under changes to AUSTRALIA's Privacy Act
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.